China Biotech Services Holdings Limited

Total Valuation

China Biotech Services Holdings Limited carries a market capitalization of 556.17M, placing it among publicly traded companies globally. Its enterprise value stands at 797.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

China Biotech Services Holdings Limited currently has 956.19M shares outstanding.

Valuation Ratios

China Biotech Services Holdings Limited trades at a trailing price-to-earnings ratio of 21.81. The price-to-sales ratio is 3.50, and the price-to-book ratio stands at -3.46.

Enterprise Valuation

On an enterprise value basis, China Biotech Services Holdings Limited trades at an EV/EBITDA multiple of 5.66 and an EV/FCF ratio of 151.66. The EV/Sales ratio of 3.76 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.66 provides insight into valuation relative to core operating earnings.

Financial Position

China Biotech Services Holdings Limited maintains a current ratio of 1.64, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.46, indicating elevated leverage, while an interest coverage ratio of -22.34 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

China Biotech Services Holdings Limited's stock has declined approximately -26.92308% over the past 52 weeks. The 50-day moving average sits at 0.67, while the 200-day moving average is 0.82.

Income Statement

Over the trailing twelve months, China Biotech Services Holdings Limited generated 211.99M in revenue and converted that into -95.45M in net income, yielding earnings per share of -0.15. EBITDA reached -118.63M, while operating income came in at -118.63M.

Balance Sheet

China Biotech Services Holdings Limited holds 72.09M in cash and equivalents against 100.40M in total debt, resulting in a net debt position of 12.75M. Total book value stands at -214.47M, with working capital of 101.70M providing operational flexibility.

Margins

China Biotech Services Holdings Limited operates with a gross margin of 16.19, reflecting its pricing power and cost economics. The operating margin of -55.96 and net profit margin of -45.03 provide insight into operational efficiency.

Stock Splits

China Biotech Services Holdings Limited's most recent stock split took place on February 23, 2016 with a 2:1 split ratio.

Scores

China Biotech Services Holdings Limited posts an Altman Z-Score of 1.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.